Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4362535 | 0.98 | HSP90AA1 (0.44) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL29770293 | 0.98 | HSP90AA1 (0.44) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL1680333 | 0.98 | MEN1 (0.40) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL23698403 | 0.97 | MEN1 (0.42) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL4358559 | 0.97 | MEN1 (0.42) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL2693562 | 0.97 | MEN1 (0.42) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL3398646 | 0.97 | MEN1 (0.42) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL15901858 | 0.97 | MEN1 (0.42) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2900812 | 0.95 | MEN1 (0.43) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Iodide SCHEMBL2894605 | 0.95 | SMN1; SMN2 (0.42) | MEN1HSP90AA1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721900-B1 | NOVEL IMIDAZOLIUM COMPOUND | KANTO KAGAKU (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-7517999-B2 | needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070191612-A1 | Needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | HIROYUKI OHNO (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1721900-A1 | NOVEL IMIDAZOLIUM COMPOUND | Kanto Kagaku Kabushiki Kaisha (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191612-A1 | Needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | SLC26A3, KCNJ11, SLC26A4 | MEN1 636/4885HSP90AA1 3528/4885KMT2A 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.